| Status: Under consideration by AWMSG Scrutiny Panel | |
Dose escalation for adults with moderately to severely active Crohn’s disease or ulcerative colitis who respond to ustekinumab at its licensed dosing but either achieve a partial response, or lose response before the next dose is due (off label use). |
|
Medicine details |
|
| Medicine name | ustekinumab |
| Formulation | solution for injection; solution for infusion |
| Reference number | 10980 |
| Indication | As above |
| BNF chapter | Gastro-intestinal system |
| Assessment type | Under consideration |
| Status | Under consideration by AWMSG Scrutiny Panel |
| Scrutiny Panel meeting date | 15/10/2026 |